Cortisol levels in different tissue samples in posttraumatic stress disorder patients versus controls : a systematic review and meta-analysis protocol by Van den Heuvel, Leigh Luella et al.
PROTOCOL Open Access
Cortisol levels in different tissue samples in
posttraumatic stress disorder patients
versus controls: a systematic review and
meta-analysis protocol
Leigh Luella van den Heuvel1* , Simonne Wright1, Sharain Suliman1, Tobias Stalder2, Clemens Kirschbaum3 and
Soraya Seedat1
Abstract
Background: Posttraumatic stress disorder (PTSD) is a disorder that develops following exposure to severely
stressful events. Altered cortisol secretion has been reported in PTSD; however, results have been inconsistent.
Previous meta-analyses of cortisol levels in PTSD have combined results of studies that have used different tissue
samples (blood, saliva, urine) for cortisol measurement and have not included newer methods of determining
cortisol levels (e.g. hair samples). In this systematic review, we will synthesise evidence from studies evaluating basal
cortisol levels in PTSD patients versus controls and stratify studies according to tissue type used for cortisol
measurement. We will also determine whether results from different tissue types can be pooled and if any specific
tissue samples have better utility in research studies on PTSD.
Methods: We will perform a systematic review of the scientific literature including all studies that have evaluated
basal or baseline cortisol levels in adults with current PTSD versus controls, with and without trauma exposure.
Independent reviewers will conduct searches in electronic databases (Medline, CINAHL, PTSDpubs, Web of Science,
Scopus, ProQuest Dissertations & Theses A&I, ClinicalTrials.gov, and ICTRP), and additional studies will be obtained
by searching the reference lists of articles. Two reviewers (LLvdH and SW) will independently conduct standardised
screening, eligibility assessments, data extraction, and quality assessments before qualitative and, if appropriate,
quantitative (meta-analysis and meta-regression) synthesis. Disagreements that arise at any stage will be resolved by
a third reviewer (ShS).
Discussion: In line with previous reviews, we expect that cortisol levels will be lower in PTSD patients than in
controls, but that patterns may vary somewhat according to the tissue sample in which cortisol is measured. This
systematic review will assist in developing a better understanding of the acute and chronic patterns of basal
cortisol secretion in PTSD and will inform future research.
Systematic review registration: PROSPERO CRD42018091874
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Background
Posttraumatic stress disorder (PTSD) develops following
exposure to an extreme stressor(s) or traumatic event(s),
such as being confronted with actual or threatened
death, serious injury, or sexual violence [1]. Symptoms,
causing significant distress or impairment of functioning,
persist for at least a month and involve repeated
re-experiencing of the traumatic event, avoidance of
trauma-related cues, negative changes in thinking and
mood, and increased arousal. In the World Health
Organization (WHO) World Mental Health (WMH)
surveys, the 12-month prevalence of PTSD in the total
sample was 1.1% [2] and the estimated lifetime preva-
lence of PTSD was 2.9% [3]. Of those with PTSD, 42% re-
ported severe role impairment in at least one domain
(work, social life, close relationships, or home maintenance)
[2] and PTSD was one of the three most disabling disorders
[4]. PTSD and other trauma- and stressor-related disorders
are distinguished from other psychiatric disorders in their
requirement of exposure to stressful events to make a diag-
nosis [1]. For PTSD, the stressful event(s) must be of a se-
vere or life-threatening nature; PTSD is, therefore, unique
in that severe stress plays a central aetiological role in the
development of a set of characteristic and persisting
symptoms.
The glucocorticoid, cortisol, is generally viewed as the
body’s chief stress hormone. Cortisol is synthesised and
released from the adrenal cortex which is a component
of the neuro-endocrine hypothalamic–pituitary–adrenal
(HPA) axis. Cortisol influences processes such as metab-
olism, immune function, digestion, and behaviour [5].
Cortisol has a baseline diurnal secretion pattern but is
also released following exposure to a stressor. It has thus
emerged as an objective biological marker of the stress
response [5–7]. A negative feedback loop in the HPA
axis regulates cortisol secretion and allows for the main-
tenance of homeostasis. Prolonged or severe stress can
lead to dysfunction of the HPA axis with resultant dys-
regulation of cortisol secretion and associated adverse
health outcomes [8, 9]. Cortisol levels can be measured
in various tissue samples reflecting cortisol secretion
over different time periods. Traditional sampling
methods, such as blood (serum and plasma), saliva, and
urine are useful for assessing acute cortisol secretion
(less than 24 h); however, newer approaches utilising hair
and nail samples can provide retrospective and chronic
patterns (weeks to months) of cortisol secretion [10–12].
The nature of PTSD as a disorder involving a chronic
maladaptive behavioural response to an extreme
stressor(s) suggests that it likely has a relationship with a
dysregulated endocrine-mediated stress response. In-
deed, HPA axis dysregulation has been reported in
PTSD; however, results have been inconsistent. A previ-
ous systematic review and meta-analysis of basal cortisol
levels in PTSD and controls reported no difference in
cortisol levels between PTSD patients and controls [13].
The authors pooled results from different tissue samples
for their primary analysis and documented significant
heterogeneity. In subgroup analysis, they found that
plasma and serum cortisol levels were significantly lower
in PTSD patients versus trauma unexposed controls
(TUC), suggesting that cortisol findings may vary ac-
cording to tissue type sampled. Furthermore, a recent
meta-analysis that only included salivary cortisol levels
reported lower cortisol levels in PTSD patients than in
controls [14]. Trauma exposure in controls may be an-
other confounding factor, as another meta-analysis that ex-
amined the association between trauma exposure in
adulthood and cortisol levels found no difference in basal
cortisol levels between PTSD patients and trauma-exposed
controls (TEC) [15]. Contrary to these findings, a meta-
analysis that separately evaluated PTSD patients and PTSD
patients with comorbid depression reported lower daily
cortisol output for both groups compared to TUC [16]. In-
consistent findings in meta-analyses could also be ascribed
to variations in tissue sample type in the included studies
and methods used in aggregating results in meta-analysis.
Systematic reviews evaluating cortisol levels in PTSD have
also not included newer tissue sampling methods, such as
hair and nail cortisol measurements. A recent meta-analysis
of hair cortisol studies reported lower hair cortisol levels in
patients with anxiety disorders (PTSD and generalised anx-
iety disorder [GAD]) [17], suggesting that adding newer tis-
sue sampling methods could enhance the understanding of
HPA axis function in PTSD.
In this systematic review, we aim to bring together all
studies that have evaluated basal cortisol levels in PTSD
patients versus controls according to the type of tissue
sampled. By analysing tissue type, we seek to develop a
better understanding of measurement of acute and
chronic patterns of basal cortisol secretion in PTSD pa-
tients versus controls. We will also seek to establish
whether data from different tissue types can be com-
bined and whether sampling a specific tissue for cortisol
measurement has greater utility in PTSD studies.
Objectives
Our objectives are as follows:
1. Our primary objective is to evaluate whether PTSD
is associated with altered basal cortisol levels by
synthesising the available evidence from primary
studies. A previous study that addressed this aim
was published more than 10 years ago [13]. Our
study involves important differences in terms of
methodological approach. In both qualitative and
quantitative synthesis (meta-analyses), we will
group studies according to the tissue type sampled.
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See ‘Additional file 1: Table summarising published
systematic reviews examining basal cortisol levels in
posttraumatic stress disorder’ for a summary of the
results of existing systematic reviews and
explanation of main differences as compared to this
protocol.
2. To evaluate whether pooling results from different
tissue samples is meaningful as this may inform
future approaches to sampling cortisol.
3. To determine the factors that influence the
relationship between basal cortisol levels and PTSD
by performing meta-regression where feasible.
4. To perform a critical evaluation of the available
literature with a view to identifying areas that
require further research.
See Table 1 for research question in PICOTS format.
Methods
This protocol was designed in accordance with the
guidelines set forth by The Cochrane Collaboration [18]
and the Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) [19] Statement. The
systematic review protocol has been registered with the
PROSPERO International prospective register of system-
atic reviews database (PROSPERO registration number:
CRD42018091874) [20]. A PROSPERO search identified
two other systematic reviews registered evaluating corti-
sol levels in PTSD. The first aims to evaluate broader HPA
axis function in PTSD, including factors such as dehydro-
epiandrosterone (DHEA) levels and changes due to psycho-
therapeutic treatment [21], and the second is focused on
evaluating 24-h urinary cortisol levels in PTSD patients and
was registered more recently than our systematic review
protocol [22]. Two reviewers (LLvdH and SW) will in-
dependently conduct standardised screening, eligibility
assessments, data extraction, and quality assessments
prior to qualitative and quantitative (meta-analyses
and meta-regression) synthesis.
Search strategy
Two independent reviewers (LLvdH and SW) will per-
form searches in electronic databases (PubMed/MED-
LINE, Cumulative Index to Nursing and Allied Health
Literature (CINAHL), PTSDpubs, Web of Science, Sco-
pus, and ProQuest Dissertations & Theses A&I) and trial
registries (ClinicalTrials.gov and International Clinical
Trials Registry Platform [ICTRP]) for published and un-
published studies. Additional studies will be identified by
searching the reference lists of relevant reviews and in-
cluded studies. No limits will be placed on publication
date or language; however, articles will only be translated
into English and/or authors contacted for information if
a study is likely to meet our inclusion criteria condi-
tional upon the title and abstract being available in Eng-
lish. Search terms based on ‘PTSD’ and ‘cortisol’ and
applicable synonyms and controlled vocabulary (MeSH
terms) will be used where available. The primary search
terms will first be formulated in MEDLINE (PubMed)
and will then be translated to the other databases. In the
databases, all fields will be searched, excluding SCOPUS
where title, abstract, and keywords will be searched. We
will not place any limitations, such as age group and
study design, on searches, but will manually exclude
studies according to inclusion and exclusion criteria. We
obtained independent peer review from an information
specialist who utilised the PRESS methodology [23] and
made changes to our search strategy and terms accord-
ing to their recommendations. The full search terms for
each of the databases are included in ‘Additional file 2:
Search terms’. Searches in databases will be rerun just
prior to analysis to identify any new studies qualifying
Table 1 Research question in PICOTS format
PICOTS Inclusion and exclusion criteria
Patients or
populations
Adults aged 18 years or older
Patients with current PTSD based on DSM/ICD criteria
Exposures Trauma exposure fulfilling DSM/ICD criteria occurring at least a month prior to assessment in PTSD patients and TEC
Comparison group(s) PTSD patients versus all controls
Subgroup analysis:
PTSD patients versus TEC
PTSD patients versus TUC
Outcomes Basal or baseline cortisol levels (mean levels and standard deviation) measured in different tissue types
Timing At least 1 month since trauma exposure in PTSD patients and TEC
Setting Any setting (inpatient, outpatient, community settings)
Study design Any study design where cortisol levels are compared in patients versus controls (e.g. cross-sectional, case-control and
cohort)
DSM, Diagnostic and Statistical Manual of Mental Disorders; ICD, International Statistical Classification of Diseases and Related Health Problems; PICOTS, Population,
Intervention, Comparison, Outcomes, Timing, Setting; PTSD, posttraumatic stress disorder; TEC, trauma-exposed controls; TUC, trauma-unexposed controls
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for inclusion. Searches will be saved and managed utilising
the reference manager ‘Mendeley’ where duplicates will be
identified and removed. Results from published and un-
published or ‘grey’ literature will be included, provided
studies fulfil the inclusion and exclusion criteria and suffi-
cient information is available to assess study quality.
Search results will be presented in a PRISMA flowchart
according to PRISMA guidelines (Additional file 3: Figure
S1 PRISMA flow diagram).
Selection criteria
Study design
Any study design that compares cortisol levels between
PTSD patients and controls will be included. The most
common designs will be cross-sectional and case–con-
trol studies, but cohort and other study designs will also
be included, as long as the studies address the main
question of this review and fulfil the inclusion/exclusion
criteria. If multiple papers related to a single study have
been published, the data from the study results will ei-
ther be combined or the article with the largest sample
size will be included.
Participants
We will include studies with adults aged 18 years and
older that compare cortisol levels between PTSD pa-
tients and controls. We will only include patients with
current, and not lifetime, PTSD according to DSM/ICD
criteria. Controls, with and without, trauma exposure
and without a history of prior PTSD will be included.
For each tissue type, we will compare cortisol levels in
PTSD patients versus all controls (AC). We will also per-
form subgroup analyses comparing PTSD patients ver-
sus TEC and versus TUC. In both patients and TEC,
trauma exposure should fulfil DSM/ICD criteria of
trauma exposure and should have occurred at least a
month prior to assessment. We will include studies
where trauma exposure is not clearly defined in our AC
group, but not in the subgroup analysis. Including a
group of AC, alongside trauma-specified controls, will
increase the number of qualifying studies and subgroup
analysis will help elucidate the importance of accounting
for trauma exposure in controls. We will include studies
with medical or psychiatric comorbidity provided the de-
tails of comorbidity are well described and comorbidity
is not expected to have a substantial impact on out-
comes. If possible, psychiatric comorbidity will be in-
cluded as a factor in meta-regression.
Outcomes
To be included in the review, sufficient data to compute
effect sizes (mean cortisol levels and standard devia-
tions) must be included in the articles or be made avail-
able from the authors on request. Baseline or basal
cortisol measurement in any tissue sample type (plasma,
serum, whole blood, saliva, urine, hair, nails, and any
others) will be included. Different time periods of sam-
pling will be included, such as morning, evening, 24-h
output, and different lengths of hair/nail samples. Mean
cortisol levels from repeated cortisol measures (e.g. over
24 h) will be included as daily cortisol output. We will
exclude studies evaluating cortisol levels in response to
psychological or pharmacological stress tests. We will
only include studies where the methods to obtain sam-
ples (e.g. time of day for acute measures, area on body
hair samples obtained from) and to determine cortisol
levels (e.g. storage conditions and assay methods used)
are clearly described. We will highlight and report separ-
ately on studies that utilised more than one tissue sam-
ple to determine cortisol levels as these studies may
assist in directly evaluating the utility of specific sam-
pling methods in PTSD studies. In our meta-analysis, we
will include each study only once and we will prioritise
the results according to the largest sample size, the sam-
ple with the most complete data, and the sample with
the newer tissue sample type (e.g. hair or nails), as the
more established sampling approaches have been evalu-
ated in prior meta-analyses.
Study selection
We will first screen the titles and abstracts of articles
and exclude articles based on inclusion/exclusion cri-
teria. We will then screen the full text of the remaining
articles and further sort the articles based on inclusion/
exclusion criteria. We will utilise an eligibility form to
capture and note reasons for including or excluding arti-
cles at this stage (Additional file 4: Eligibility form). The
eligibility form will be piloted on a subset of studies, and
if necessary, modifications will be made. Titles, abstracts,
and full texts will be independently reviewed by re-
viewers 1 and 2 (LLvdH and SW). Any disagreements
will be discussed, and if not resolved, eligibility will be
determined with the assistance of a third reviewer (ShS).
For each stage of review, we will calculate inter-rater
agreement utilising the kappa statistic.
Corresponding authors of manuscripts will be con-
tacted via email in the following cases: to obtain a copy
of the manuscript if one cannot be obtained; if a manu-
script in a foreign language appears eligible for inclusion,
the authors will be contacted to enquire whether the de-
tails of the study including the results are available in
English; if additional information is required to deter-
mine study eligibility; to ask for clarification of methods
and specific results if these were not included in the
manuscript; authors on trial databases will be contacted
to enquire whether study details and results are avail-
able. If no response is received within 2 weeks, a
follow-up email will be sent. If no response is received
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within another 2 weeks, non-response will be noted and
the study excluded. Studies may still be included if au-
thors respond prior to final data analysis.
Data extraction
Data will be abstracted by two independent reviewers
(LLvdH and SW). Data will be entered and managed uti-
lising the Research Electronic Data Capture (REDCap)
database application [24]. REDCap is a system for struc-
tured, clinical study data capture and is designed to
comply with HIPAA regulations. Access control will be
password-protected and role-based. The data extraction
form will be piloted prior to formal data abstraction, and
if necessary, modifications will be made (Additional file 5:
Data extraction form). Data extracted will include study
characteristics such as study design, setting, and sample
size; basic descriptive data (e.g. age, gender, ethnicity) of
patients and controls; trauma-related data such as
trauma type, trauma load, and duration since trauma;
PTSD-related data such as method to determine diagno-
sis, PTSD severity, duration of illness; physical data such
as BMI and blood pressure and any medical or psychi-
atric comorbidity; cortisol-related data such as tissue
type, date and time of sampling, method used to sample
and analyse cortisol, mean cortisol levels and standard
deviations, and the unit of measurement for patients and
controls. If cortisol is measured at multiple time points,
we will extract data for each time point and the mean
total cortisol over a set period (e.g. 24 h) if available.
Quality (risk of bias) assessment
Two reviewers (LLvdH and SW) will perform independent
quality or risk of bias (ROB) assessments, and any dis-
agreements will be resolved by a third reviewer (ShS).
Inter-rater reliability will be determined (kappa statistic).
We will perform ROB assessments with a modified ver-
sion of the Newcastle–Ottawa scale (NOS) [25] adapted
for use in observational studies [26] (Additional file 6:
Modified Newcastle Ottawa Scale). The scale assesses for
four types of bias (selection bias, performance bias, detec-
tion bias, and information bias) with seven questions rated
from 0 to 3 with higher scores reflecting lower ROB. In
addition, we will pilot a tool for ROB assessment designed
for specific use in our review (Additional file 7: Risk of
bias (ROB) assessment), based on the guidelines provided
by the Agency for Healthcare Research and Quality
(AHRQ) [27]. We utilised the approach and applicable
components (blinding of outcome, incomplete outcome
data, selective reporting) from the Cochrane Risk Of Bias
Tool [28] as well as modified components from the NOS.
The ROB assessment contains 11 items assessing for se-
lection bias, performance bias, detection bias, attrition
bias, reporting bias, and funding or conflict of interest
bias. Each item will be rated as ‘low risk of bias’, ‘high risk
of bias’, or ‘unclear risk of bias’, and the results for each
study will be presented graphically (Additional file 8: Ex-
ample risk of bias (ROB) figure). The ROB assessment
tool will be piloted on a subset of studies, and if required,
revisions will be made. We will report on and compare
ROB bias assessments obtained with both tools as the
modified NOS will allow for comparability with existing
studies, whereas the ROB assessment tool designed for
our study utilises examples and explanations specific to
PTSD and cortisol studies, such as specific methods to de-
termine TE and patient status and includes assessments
for additional types of bias not assessed with the modified
NOS. We will utilise the Grading of Recommendations,
Assessment and Evaluation (GRADE) approach to report
the quality of evidence and strength of recommendations
[29]. The influence of bias on quantitative outcomes will
be assessed by performing sensitivity analysis.
Data synthesis
Qualitative synthesis Individual studies will be sum-
marised utilising evidence tables. At a minimum, we will
include the authors, year of publication, setting, study
design, sample sizes, age, sex, ethnicity, trauma type,
time since trauma, trauma and PTSD measures, PTSD
severity, PTSD duration, comorbidity, medication use,
time or time period of cortisol assessment, cortisol
levels, measurement of cortisol levels, and confounders
(see ‘Additional file 9: List of potential moderators’ for a
full list of moderators that will be included). Data will be
organised according to patient and control groups for
each study. We will perform a qualitative evaluation of
heterogeneity by examining factors such as study design,
trauma exposure, settings, populations, and outcome
measurements.
Quantitative synthesis Where appropriate, we will per-
form a meta-analysis for each tissue type sampled.
Meta-analysis will only be performed where there are at
least two comparable studies with sufficient data avail-
able. In articles where results are not reported as means
and standard deviations, study authors will be contacted
to obtain these summary statistics. If these summary sta-
tistics cannot be obtained, we will transform available
summary statistics (e.g. median and interquartile range)
utilising available formulas [30]. We will compare stan-
dardised mean difference (SMD) in cortisol levels be-
tween PTSD cases and all controls, and if possible, we
will perform a subgroup analysis based on trauma ex-
posure status of controls (TEC and TUC). We will util-
ise the SMD to allow for pooling of data from studies
utilising different methods to determine cortisol (e.g.
ELISA versus LC-MS and different tissue samples).
Hedge’s g will be used for studies with smaller sample
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sizes. As we expect there to be heterogeneity in study
design, we will utilise a random-effects model (DerSimo-
nian and Laird) [31]. Results will be graphically repre-
sented utilising forest plots. Heterogeneity will be
assessed utilising the Cochrane’s Q (chi-squared test)
and I2 statistics and by visually inspecting the forest
plots. If significant heterogeneity exists, we will evaluate
whether any specific studies significantly influenced the
results by excluding each individual study and examining
its impact on the pooled SMD and between-study het-
erogeneity. If there are a sufficient number of studies per
tissue type (e.g. ten), we will perform meta-regression, in
addition to the subgroup analysis according to trauma
exposure status of controls. Potential moderators that
will be included in the meta-regression will be year of
publication, age, sex, trauma type, time since index
trauma, developmental stage of trauma exposure, PTSD
severity, psychiatric comorbidity, time period of sam-
pling (e.g. time of day for acute measures and length of
hair sample representing retrospective window for hair
sampling), and method used to determine cortisol level
(ELISA or LC-MS). Moderators will first be entered indi-
vidually and those with a significance level of 0.1 will be
entered in a multivariate meta-regression. The meta-re-
gression will be conducted using a restricted maximum
likelihood (REML) model. To address the issue of statis-
tically dependent effect sizes that may arise from mul-
tiple methods of cortisol assessment within a study or
from either repeated measures within a study that may
have a longitudinal design, robust variance estimation
procedures in meta-regression will be used. We will
evaluate for effect of studies at high ROB and for the ef-
fect of study design type by entering the total score and
domain sub-scores obtained on the modified NOS and
study design type into separate regression models. Fur-
ther sensitivity analyses will be performed to assess the
influence of studies assessed as having a high ROB, by
excluding studies with a high ROB and evaluating the
impact on main outcomes. We will assess for small
study effects with funnel plots (for analyses with 10 or
more studies), and statistical tests for asymmetry (Egger
test) will be performed where appropriate. If asymmetry
is present, we will perform the trim-and-fill procedure
[32]. Data will be analysed with STATA IC version 15.
We will present the results for each tissue type sampled
in a summary of findings table. As a final step, we will pool
the results of studies utilising different tissue types together
utilising a cumulative approach to demonstrate trends ac-
cording to tissue type sampled. We anticipate that we may
have to make certain modifications to our meta-analysis ap-
proach based on the data collected (e.g. certain important
variations may only be evident once the data have been col-
lated). We will stipulate the rationale for any modifications
and clearly specify post-hoc analyses.
Dissemination of results
The manuscript will be submitted for publication to an
appropriate peer-reviewed journal, with preference for
an open-access journal to enhance both accessibility and
visibility. The results will also be presented at relevant
conferences and meetings.
Discussion
In line with previous reviews, we expect that cortisol
levels will generally be lower in PTSD patients than in
controls, with larger difference observed when compared
to TUC than TEC. We expect that patterns (i.e. the dir-
ectionality of cortisol levels in PTSD cases compared
with controls) will be similar across tissue type but
case–control differences may not be statistically signifi-
cant for all tissue types sampled. Some of the variability
may be the result of the time window of cortisol meas-
urement, as reflected by the tissue type sampled. Sys-
tematically identifying this variability may assist in better
delineating acute and chronic patterns of basal cortisol
secretion in PTSD. We will utilise outcomes of this re-
view to identify aspects requiring additional investigation
as well as provide suggestions as to which tissue sample
types may have better utility for PTSD studies.
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